Nasal and nasal-type natural killer/T-cell lymphoma

S. Hirakawa, M. Kuyama, S. Takahashi, Osamu Yamasaki, H. Kanzaki, T. Teshima, M. Harada, Y. Ma, T. Kawabata, Tadashi Yoshino, J. Arata

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Nasal and nasal-type natural killer (NK)/T-cell lymphomas follow an aggressive course and have a poor prognosis. Recent pathologic studies suggest that the disease is a malignant proliferation of NK cells, which often express CD56. An association with the Epstein-Barr virus has also been reported. Skin involvement occurred in each of the 3 patients studied. Radiation therapy provided some benefit to the patients in the early stages. Conventional chemotherapies were not effective. To overcome this multiple- drug resistance of the tumor cells, cyclosporine and high-dose chemotherapy was combined with peripheral-blood stem-cell transplantation. The average life span from the onset of the disease for our patients was 9.6 months. Further improvement in the management of nasal and nasal-type NK/T-cell lymphomas is necessary.

Original languageEnglish
Pages (from-to)268-272
Number of pages5
JournalJournal of the American Academy of Dermatology
Volume40
Issue number2 I
DOIs
Publication statusPublished - 1999

Fingerprint

Natural Killer T-Cells
T-Cell Lymphoma
Nose
Peripheral Blood Stem Cell Transplantation
Drug Therapy
Multiple Drug Resistance
Human Herpesvirus 4
Natural Killer Cells
Cyclosporine
Radiotherapy
Skin
Neoplasms

ASJC Scopus subject areas

  • Dermatology

Cite this

Hirakawa, S., Kuyama, M., Takahashi, S., Yamasaki, O., Kanzaki, H., Teshima, T., ... Arata, J. (1999). Nasal and nasal-type natural killer/T-cell lymphoma. Journal of the American Academy of Dermatology, 40(2 I), 268-272. https://doi.org/10.1016/S0190-9622(99)70204-5

Nasal and nasal-type natural killer/T-cell lymphoma. / Hirakawa, S.; Kuyama, M.; Takahashi, S.; Yamasaki, Osamu; Kanzaki, H.; Teshima, T.; Harada, M.; Ma, Y.; Kawabata, T.; Yoshino, Tadashi; Arata, J.

In: Journal of the American Academy of Dermatology, Vol. 40, No. 2 I, 1999, p. 268-272.

Research output: Contribution to journalArticle

Hirakawa, S, Kuyama, M, Takahashi, S, Yamasaki, O, Kanzaki, H, Teshima, T, Harada, M, Ma, Y, Kawabata, T, Yoshino, T & Arata, J 1999, 'Nasal and nasal-type natural killer/T-cell lymphoma', Journal of the American Academy of Dermatology, vol. 40, no. 2 I, pp. 268-272. https://doi.org/10.1016/S0190-9622(99)70204-5
Hirakawa, S. ; Kuyama, M. ; Takahashi, S. ; Yamasaki, Osamu ; Kanzaki, H. ; Teshima, T. ; Harada, M. ; Ma, Y. ; Kawabata, T. ; Yoshino, Tadashi ; Arata, J. / Nasal and nasal-type natural killer/T-cell lymphoma. In: Journal of the American Academy of Dermatology. 1999 ; Vol. 40, No. 2 I. pp. 268-272.
@article{5ba1f83497764322a195583e3ace4a2b,
title = "Nasal and nasal-type natural killer/T-cell lymphoma",
abstract = "Nasal and nasal-type natural killer (NK)/T-cell lymphomas follow an aggressive course and have a poor prognosis. Recent pathologic studies suggest that the disease is a malignant proliferation of NK cells, which often express CD56. An association with the Epstein-Barr virus has also been reported. Skin involvement occurred in each of the 3 patients studied. Radiation therapy provided some benefit to the patients in the early stages. Conventional chemotherapies were not effective. To overcome this multiple- drug resistance of the tumor cells, cyclosporine and high-dose chemotherapy was combined with peripheral-blood stem-cell transplantation. The average life span from the onset of the disease for our patients was 9.6 months. Further improvement in the management of nasal and nasal-type NK/T-cell lymphomas is necessary.",
author = "S. Hirakawa and M. Kuyama and S. Takahashi and Osamu Yamasaki and H. Kanzaki and T. Teshima and M. Harada and Y. Ma and T. Kawabata and Tadashi Yoshino and J. Arata",
year = "1999",
doi = "10.1016/S0190-9622(99)70204-5",
language = "English",
volume = "40",
pages = "268--272",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2 I",

}

TY - JOUR

T1 - Nasal and nasal-type natural killer/T-cell lymphoma

AU - Hirakawa, S.

AU - Kuyama, M.

AU - Takahashi, S.

AU - Yamasaki, Osamu

AU - Kanzaki, H.

AU - Teshima, T.

AU - Harada, M.

AU - Ma, Y.

AU - Kawabata, T.

AU - Yoshino, Tadashi

AU - Arata, J.

PY - 1999

Y1 - 1999

N2 - Nasal and nasal-type natural killer (NK)/T-cell lymphomas follow an aggressive course and have a poor prognosis. Recent pathologic studies suggest that the disease is a malignant proliferation of NK cells, which often express CD56. An association with the Epstein-Barr virus has also been reported. Skin involvement occurred in each of the 3 patients studied. Radiation therapy provided some benefit to the patients in the early stages. Conventional chemotherapies were not effective. To overcome this multiple- drug resistance of the tumor cells, cyclosporine and high-dose chemotherapy was combined with peripheral-blood stem-cell transplantation. The average life span from the onset of the disease for our patients was 9.6 months. Further improvement in the management of nasal and nasal-type NK/T-cell lymphomas is necessary.

AB - Nasal and nasal-type natural killer (NK)/T-cell lymphomas follow an aggressive course and have a poor prognosis. Recent pathologic studies suggest that the disease is a malignant proliferation of NK cells, which often express CD56. An association with the Epstein-Barr virus has also been reported. Skin involvement occurred in each of the 3 patients studied. Radiation therapy provided some benefit to the patients in the early stages. Conventional chemotherapies were not effective. To overcome this multiple- drug resistance of the tumor cells, cyclosporine and high-dose chemotherapy was combined with peripheral-blood stem-cell transplantation. The average life span from the onset of the disease for our patients was 9.6 months. Further improvement in the management of nasal and nasal-type NK/T-cell lymphomas is necessary.

UR - http://www.scopus.com/inward/record.url?scp=0032968137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032968137&partnerID=8YFLogxK

U2 - 10.1016/S0190-9622(99)70204-5

DO - 10.1016/S0190-9622(99)70204-5

M3 - Article

VL - 40

SP - 268

EP - 272

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2 I

ER -